The Do IT Study

The purpose of this study is to see whether people living with HIV who gained a significant amount of weight after starting an antiretroviral therapy (ART) regimen that included an integrase strand transfer inhibitor (INSTI) in combination with tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir alafenamide/lamivudine (TAF/3TC) could gain less weight, or might lose weight, after an ART regimen switch. The study will also assess if a switch in ART leads to differences in metabolic conditions (how the body stores and uses energy), cardiovascular health (the heart and blood vessels), and bone health.